Revance Therapeutics, Inc. (RVNC)

NASDAQ: RVNC · IEX Real-Time Price · USD
2.800
-0.020 (-0.71%)
Jun 17, 2024, 4:00 PM EDT - Market closed
-0.71%
Market Cap 292.45M
Revenue (ttm) 236.65M
Net Income (ttm) -317.35M
Shares Out 104.45M
EPS (ttm) -3.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,441,957
Open 2.800
Previous Close 2.820
Day's Range 2.740 - 2.860
52-Week Range 2.570 - 29.430
Beta 1.05
Analysts Buy
Price Target 12.00 (+328.57%)
Earnings Date Aug 6, 2024

About RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Ph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2014
Employees 597
Stock Exchange NASDAQ
Ticker Symbol RVNC
Full Company Profile

Financial Performance

In 2023, RVNC's revenue was $234.04 million, an increase of 76.55% compared to the previous year's $132.57 million. Losses were -$323.99 million, -9.10% less than in 2022.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 328.57% from the latest price.

Price Target
$12.0
(328.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

3 days ago - Business Wire

Revance to Participate in Upcoming Investor Conferences

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Investor Conferences.

20 days ago - Business Wire

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update.

5 weeks ago - Business Wire

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia.

5 weeks ago - Business Wire

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024.

6 weeks ago - Business Wire

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting.

2 months ago - Business Wire

VKTX, JANX and these biotech stocks are surging in 2024

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

2 months ago - Invezz

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $100 Million Public Offering of Common Stock.

3 months ago - Business Wire

Revance Announces Proposed Public Offering of Common Stock

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Proposed Public Offering of Common Stock.

3 months ago - Business Wire

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update.

3 months ago - Business Wire

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.

4 months ago - Business Wire

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®.

4 months ago - Business Wire

Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference.

4 months ago - Business Wire

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook.

5 months ago - Business Wire

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

NASHVILLE--(BUSINESS WIRE)--Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update.

7 months ago - Business Wire

Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics.

7 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advis...

8 months ago - PRNewsWire

Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023.

8 months ago - Business Wire

Revance Provides Corporate Update at Investor Day

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update at Investor Day.

9 months ago - Business Wire

Revance to Host Investor Day on September 19, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Host Investor Day on September 19, 2023.

10 months ago - Business Wire

Revance shares gain 8% after FDA approval of cervical dystonia treatment

Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dy...

11 months ago - Market Watch

Revance's Botox rival gets FDA approval for painful neck muscle condition

The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Boto...

11 months ago - Reuters

U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

NASHVILLE, Tenn.--(BUSINESS WIRE)--U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia.

11 months ago - Business Wire

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update.

11 months ago - Business Wire

Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023.

11 months ago - Business Wire